Close Icon
Forbes October 20, 2021

After Helping Pfizer Speed Up Its Vaccine Trials, Saama Technologies Strikes A $430 Million Deal With Carlyle

Private Equity Powerhouse Leads Group of Investors Bullish on AI

Leading business publication Forbes broke the news of Saama’s $430 million funding deal with a collection of investors led by The Carlyle Group.

The majority stake acquisition marks a bet by Carlyle “on the growing importance of AI, machine learning and big data in the process of drug development,” reports staff writer Kevin Dowd. “Several healthcare heavyweights are also bullish on Saama’s potential: The corporate venture capital arms of Pfizer, Amgen, Merck and McKesson are all joining Carlyle as co-investors.”

Read the Article

Access Out-of-the-Box Features in 4 Weeks—Guaranteed.

Saama can put you on the fast track to clinical trial process innovation.